Compare eBay Inc (EBAY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
eBay Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? eBay Inc trades at $112.86 (market cap $50.07B), while Vertex Pharmaceuticals Incorporated trades at $482 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.4× eBay Inc's market cap, and eBay Inc pays a 1.1% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| EBAY | VRTX | |
|---|---|---|
Market Cap | $50.07B | $121.09B |
Volume | 5,186,418 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $529.59 |
52-Week Low | $76.79 | $366.54 |
Enterprise Value | $53.41B | $115.83B |
Dividend Yield | 1.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $112.54, down 2.22% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters with Q1 2026 EPS of $1.66 beating expectations of $1.58. Revenue growth accelerated to $11.1B in 2025, while maintaining robust profitability with 71.79% gross margins and 17.61% net income margin. Recent developments include the UK regulator clearing eBay's acquisition of Depop and ongoing market speculation about GameStop's takeover interest.
EBAY presents a mixed investment case with strong fundamentals offset by acquisition uncertainty. The stock trades above analyst consensus target of $108.78 despite recent weakness. Key opportunities include continued earnings momentum and advertising revenue growth, while risks center on competitive pressures and potential takeover volatility. Institutional sentiment remains cautiously optimistic with 46% buy ratings.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
